This healthcare stock could skyrocket anytime
Vertex Pharmaceuticals (NASDAQ: VRTX) boasts an impressive track record, establishing itself as a leading biotech firm over the last decade. The company has demonstrated a keen emphasis on addressing a specific rare lung disease, cystic fibrosis (CF). Despite facing no direct competition in this niche, Vertex has strategically chosen to broaden its portfolio by introducing…